Portage Biotech Inc. (PRTG) Stock Analysis
DELISTED 2021
What happened to Portage Biotech Inc. (PRTG) stock?
Portage Biotech Inc. (PRTG) no longer trades on public markets. It was delisted in April 2021. The figures below are historical and are not a current quote.
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Portage Biotech Inc. (PRTG) trades at $6.81. Portage Biotech Inc. is a pharmaceutical and biotechnology company focused on researching and developing innovative products. Market cap: $15.5M, Sector: Healthcare.
Last analyzed: Mar 16, 2026Analyst Coverage for PRTG: PRTG does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PRTG against Healthcare peers across nine fundamental dimensions and assigns a neutral fundamental signal based on the underlying data.
Portage Biotech Inc. (PRTG) Healthcare & Pipeline Overview
Portage Biotech Inc. is a biotechnology firm researching and developing pharmaceutical products, including immunotherapies and cell-based therapies, with a focus on oncology and immune system modulation. Their pipeline features early-stage clinical trials and pre-clinical programs targeting solid tumors and inflammatory diseases, positioning them in the competitive biotechnology landscape.
What Is the Investment Thesis for PRTG?
Portage Biotech Inc. presents a high-risk, high-reward investment profile characteristic of early-stage biotechnology companies. The company's value is primarily driven by its pipeline of pre-clinical and early-stage clinical assets, particularly INT230-6, which is currently in Phase I/II clinical trials. Successful clinical trial outcomes and strategic partnerships could serve as significant catalysts. Key risks include clinical trial failures, regulatory hurdles, and the need for additional funding, especially given the company's market capitalization of $15.5M and negative P/E ratio of -0.05. The company's beta of 0.64 suggests lower volatility compared to the broader market, but the inherent risks of biotechnology investments remain substantial.
Based on FMP financials and quantitative analysis
PRTG Key Highlights
Market capitalization of $15.5M reflects its small-cap status within the biotechnology sector.
- P/E ratio of -0.05 indicates the company is currently not profitable, typical for early-stage biotech firms focused on R&D.
- Beta of 0.64 suggests the stock is less volatile than the overall market.
- Focus on immuno-oncology and cell-based therapies aligns with current trends in cancer treatment.
- Pipeline includes multiple pre-clinical and early-stage clinical assets, offering potential for future growth.
Who Are PRTG's Competitors?
PRTG is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CSCI COSCIENS Biopharma Inc. | $2.72 | +0.00% | $8.57M | 63 |
| CYAD Celyad Oncology S.A. | $0.47 | -12.96% | $14.2M | 57 |
| IMNN Imunon, Inc. | $1.58 | +0.64% | $6.64M | — |
| KA Kineta, Inc. | $0.57 | -30.77% | $7.05M | 45 |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PRTG's Key Strengths?
Innovative technology platforms like CellPorter.
- Diverse pipeline of pre-clinical and early-stage assets.
- Focus on high-growth areas like immuno-oncology.
- Lean operational structure allows for efficient resource allocation.
What Are PRTG's Weaknesses?
Limited financial resources compared to larger pharmaceutical companies.
- Early-stage pipeline carries significant clinical and regulatory risk.
- Reliance on partnerships for clinical development and commercialization.
- Small team size may limit operational capacity.
What Could Drive PRTG Stock Higher?
PRTG catalyst: Data readout from Phase I/II clinical trials of INT230-6 for solid tumors (Estimated: Q4 2026).
- Announcement of new strategic partnerships or licensing agreements (Ongoing).
- Progress in pre-clinical development of IMM60 and IMM65 (Ongoing).
- Expansion of CellPorter technology platform into new therapeutic areas (Ongoing).
- Publication of peer-reviewed articles on the company's technologies (Ongoing).
What Are the Key Risks for PRTG?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures for lead drug candidates (Ongoing).
- Regulatory delays or rejection of drug approvals (Ongoing).
- Competition from larger pharmaceutical companies with greater resources (Ongoing).
- Inability to secure additional funding to support research and development (Ongoing).
- Intellectual property disputes or challenges to patent protection (Ongoing).
What Are the Growth Opportunities for PRTG?
- Advancement of INT230-6: The ongoing Phase I/II clinical trials for INT230-6 in solid tumors represent a near-term growth opportunity. Positive trial results could lead to partnerships, licensing agreements, or further clinical development, potentially unlocking significant value. The solid tumor treatment market is projected to reach $400 billion by 2030, offering a substantial addressable market.
- Development of IMM60 and IMM65: These iNKT cell activator and nanoparticle vaccine programs offer potential in immuno-oncology. Pre-clinical and early clinical data will be crucial in determining their viability. The market for cancer vaccines is expected to grow to $15 billion by 2028, driven by advancements in personalized medicine.
- Expansion of CellPorter Technology: The CellPorter cell permeable peptide platform has applications beyond oncology, including drug delivery and gene therapy. Exploring partnerships and collaborations to leverage this technology in other therapeutic areas could diversify revenue streams. The drug delivery market is projected to reach $240 billion by 2027.
- Strategic Partnerships and Licensing: Portage Biotech's lean operational structure necessitates strategic partnerships to advance its pipeline. Securing licensing agreements or collaborations with larger pharmaceutical companies could provide funding and expertise to accelerate development. The partnering and licensing market in biotechnology is valued at over $100 billion annually.
- SBI-101 for Acute Kidney Injury: The SBI-101 blood-conditioning technology targets acute kidney injury, a significant unmet medical need. Positive pre-clinical data and subsequent clinical trials could position SBI-101 as a novel therapy in this area.
What Threats Does PRTG Face?
- Clinical trial failures can significantly impact valuation.
- Regulatory hurdles and delays in drug approval.
- Competition from larger pharmaceutical companies with greater resources.
- Economic downturns can impact access to funding and investment.
What Are PRTG's Competitive Advantages?
- Proprietary technology platforms like CellPorter provide a competitive edge in drug delivery.
- Patent protection on key drug candidates and technologies creates barriers to entry.
- Focus on innovative immuno-oncology approaches differentiates them from competitors.
- Early-stage pipeline offers potential for high returns if successful.
What Does PRTG Do?
Portage Biotech Inc., along with its subsidiaries, is dedicated to the research and development of pharmaceutical and biotechnology products. Founded with the aim of creating innovative therapies, the company has focused on developing a diverse pipeline of products targeting various diseases, particularly in the field of immuno-oncology. Their portfolio includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6, currently in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology designed to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. The company is also exploring nanolipogel technology for use in immune-oncology and developing antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. Furthermore, Portage Biotech is developing antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments, as well as FOXO4-P53 modulator and C-RAF inhibitor. Based in Tortola, British Virgin Islands, Portage Biotech operates with a lean team of 7 employees, emphasizing strategic partnerships and collaborations to advance its research and development programs.
What Products and Services Does PRTG Offer?
- Researches and develops pharmaceutical products.
- Focuses on biotechnology products.
- Develops iNKT cell activators (IMM60).
- Creates PLGA-nanoparticle combined peptide vaccines (IMM65).
- Conducts clinical trials for solid tumor treatments (INT230-6).
- Develops small molecules targeting interferon genes (STING).
- Utilizes cell permeable peptide platform technology (CellPorter).
- Develops blood-conditioning technology for immune system balance (SBI-101).
How Does PRTG Make Money?
- Develops and patents novel therapeutic technologies.
- Out-licenses or partners with other pharmaceutical companies for clinical development and commercialization.
- Seeks grant funding and venture capital to support research and development activities.
- Focuses on early-stage drug development and proof-of-concept studies.
What Industry Does PRTG Operate In?
Portage Biotech operates within the highly competitive biotechnology industry, characterized by rapid innovation, stringent regulatory requirements, and significant investment in research and development. The immuno-oncology market, in particular, is experiencing substantial growth, driven by the increasing prevalence of cancer and the demand for more effective and targeted therapies. Companies like CSCI, CYAD, IMNN, KA, and NTBL represent the competitive landscape, each pursuing novel approaches to cancer treatment. Portage Biotech's success hinges on its ability to differentiate its pipeline, secure funding, and navigate the complex regulatory environment.
Who Are PRTG's Key Customers?
- Pharmaceutical companies seeking to license or acquire novel therapeutic technologies.
- Patients who may benefit from the company's therapies, pending regulatory approval.
- Research institutions and universities interested in collaborating on drug development.
- Investors seeking exposure to early-stage biotechnology companies.
Forward Outlook
Wall Street analysts project Portage Biotech Inc. revenue of about $97K for fiscal 2026, with EPS near $-10.40.
PRTG Valuation & Market Position
With a $15.5M market cap, Portage Biotech Inc. sits in the micro-cap segment of the market.
Key Financial Metrics
Return on assets is -64.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -61.5%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.88 means current liabilities exceed short-term assets, a liquidity point worth watching.
Financial Health
Portage Biotech Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
Company Profile
Portage Biotech Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Tortola, VG. The company is led by CEO Alexander Pickett. PRTG has traded publicly since 2002.
PRTG Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Portage's future, indicating that those closest to the company believe in its potential.
- Community sentiment has shifted positively as recent announcements about pipeline developments have sparked interest among investors.
- The ongoing advancements in their clinical trials have generated optimism, aligning with broader trends in biotech innovation.
- Social media discussions highlight a growing recognition of Portage's unique position in the immunotherapy space, attracting attention from retail investors.
Bear Case
- Concerns about the competitive landscape in the biotech sector are prevalent, as many firms are racing to develop similar therapies.
- Recent regulatory challenges faced by biotech companies have raised doubts about the approval timelines for Portage's products.
- Community sentiment has shown volatility, with some investors expressing skepticism about the sustainability of recent hype surrounding the company.
- Market perception remains cautious due to the inherent risks associated with biotech investments, particularly in early-stage companies.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PRTG Latest News
No recent news available for PRTG.
Leadership: Alexander Pickett
CEO
Alexander Pickett serves as the CEO of Portage Biotech Inc., leading a team of 7 employees. His background includes extensive experience in the biotechnology and pharmaceutical industries, with a focus on corporate strategy, business development, and financial management. He has held leadership positions in various biotech companies, contributing to strategic planning and execution. Pickett's expertise spans across drug development, licensing, and commercialization.
Track Record: Under Alexander Pickett's leadership, Portage Biotech Inc. has focused on advancing its pipeline of immuno-oncology assets and securing strategic partnerships. Key milestones include the progression of INT230-6 into Phase I/II clinical trials and the continued development of the CellPorter technology platform. His tenure has been marked by a focus on efficient resource allocation and strategic decision-making to maximize shareholder value.
Portage Biotech Inc. Healthcare Stock: Key Questions Answered
What happened to Portage Biotech Inc. (PRTG) stock?
Portage Biotech Inc. (PRTG) no longer trades on public markets. It was delisted in April 2021. The figures below are historical and are not a current quote.
Can I still buy PRTG shares?
No. PRTG stopped trading on public markets in April 2021, so the shares are not available through a broker. Anything you see quoted for PRTG elsewhere is historical data, not a live market.
Are the figures on this page current?
No. Every number here is the last value recorded before PRTG stopped trading. Nothing on this page updates, and none of it is a current quote.
Why does this page still exist?
Because people still search for what happened to Portage Biotech Inc.. An archived profile that states the delisting plainly is more useful than a dead link — provided it is labelled as history, which is what this page does.
What does Portage Biotech Inc. do?
Portage Biotech Inc. is a biotechnology company that researches and develops pharmaceutical products, with a focus on immuno-oncology and cell-based therapies. The company's pipeline includes iNKT cell activators, nanoparticle vaccines, and therapies targeting solid tumors and immune system modulation. They aim to develop and out-license novel therapeutic technologies for clinical development and commercialization, partnering with larger pharmaceutical companies to bring innovative treatments to market.
What do analysts say about PRTG stock?
Given the pending AI analysis and limited analyst coverage for Portage Biotech Inc. (PRTG), a comprehensive consensus view is unavailable. However, as a small-cap biotechnology company with a focus on early-stage drug development, PRTG's valuation is highly dependent on the success of its clinical trials and strategic partnerships. Investors should carefully consider the inherent risks and potential rewards associated with investing in early-stage biotechnology companies before making any investment decisions.
What are the main risks for PRTG?
The primary risks for Portage Biotech Inc. include clinical trial failures, regulatory hurdles, and the need for additional funding. As an early-stage biotechnology company, the success of PRTG is heavily reliant on the positive outcomes of its clinical trials. Negative results could significantly impact the company's valuation. Regulatory delays or rejection of drug approvals could also hinder progress.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on publicly available sources and may be subject to change.
- AI analysis is pending and may provide additional insights.
- Investment in early-stage biotechnology companies carries significant risk.